Burrows Scott L sold $533K of SYRE
Burrows Scott L (Chief Financial Officer) sold 7,500 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $71.06 ($69.75–$72.06, $0.53M total) across 3 trades on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
While the CFO's sale reduces his ownership, the transaction size is modest relative to the company's market cap, likely resulting in limited price movement.
Market read
The filing provides fresh data on insider holdings, useful for short‑term sentiment assessment.
What to watch
Recent positive clinical trial updates may offset any negative perception from the sale.
Background
SEC Form 4 filing discloses insider transactions; such filings are primary sources of corporate insider activity.
Ticker impact
CFO Burrows Scott L sold 7,500 shares for $533K via a 10b5-1 plan, reducing his stake to 97,994 shares.
potential slight downward pressure as the market prices the CFO's reduced holding
Sale size is modest but involves the CFO; 10b5-1 plans are pre‑arranged, so the market may view it as a neutral routine transaction.
Market effects
Biotech sector may see minor impact as insider sales are watched for sentiment cues.
U.S. equity markets, particularly Nasdaq biotech listings.
Limited to investors tracking Spyre Therapeutics.
Counterpoint
The sale could be a routine 10b5‑1 execution, not a signal of deteriorating fundamentals.
Key entities
- companySpyre Therapeutics, Inc.
Biotech firm focused on therapeutic development, ticker SYRE.
